证券代码：301188 证券简称：力诺药包 公告编号：2025-074 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据山东力诺医药包装股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日召开 的第四届董事会第十二次会议决议，公司董事会定于 2025 年 9 月 5 日召开 2025 年第二 次临时股东会。现将有关事项通知如下： 一、会议召开基本情况 章、规范性文件和《公司章程》的有关规定。 现场会议召开时间：2025 年 9 月 5 日（星期五）14:50 网络投票时间： 其中，通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时 间为：2025 年 9 月 5 日 9:15-9:25、9:30—11:30，13:00—15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为：2025 年 9 月 5 日 9:15-15:00。 （1）现场投票：股东本人出席现场会议或者通过授权他人出席现场会议； （2）网络投票：本次股东会将通过深圳证券交易所交易 ...

| 编制单位：山东力诺医药包装股份有限公 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 司 | | | | | | | | 单位：万元 | | | | | 占用方与上 | 上市公司核 | 2025 年期初 | | 2025 | 年半年度占 | | 2025 年 | | 半年 | | | | | | | | | | | 非经营性 | 资金占用 | | | | 占用累计发生 | | | | | | 年度期末 | 占用形成 | | | | | | | | | | | | 市公司 | 算的会计科 | 占用资金余 | | | 用资金的利息 | | 度偿还 | | 累计发 | | 占用性质 | | | | | | | | | 资金占用 | 方名称 | | | | 金额（不含利 | | | | 占 | | 用资金 | 原因 | | | | | | | | | | | | 的关联关系 | 目 | 额 | | （如有） | | 生金额 | | | | | | | 息） | | | | 余额 | | | 控股 ...

证券代码：301188 证券简称：力诺药包 公告编号：2025-073 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）关联交易的基本情况 根据山东力诺医药包装股份有限公司（以下简称"公司"或"力诺药包"） 的发展规划，为盘活公司闲置土地资源，借助力诺集团股份有限公司（简称"力 诺集团"）丰富的园区建设、运营、管理经验，公司拟与力诺集团公司共同投资 设立合资公司力诺创新科技(商河)有限公司（暂定名称，具体以市场监督管理部 门登记为准），建设"科创中心及配套设施建设项目"。其中公司以土地出资， 持股比例 49%，力诺集团以现金出资，持股比例 51%。 （二）本次交易构成关联交易 本次共同投资方力诺集团为公司控股股东力诺投资控股集团有限公司的控股 股东，根据《深圳证券交易所创业板股票上市规则》及《公司章程》等相关规定， 力诺集团为公司关联法人，本次交易构成关联交易。 （三）本次交易的表决情况 公司于 2025 年 8 月 19 日召开第四届董事会第十二次会议，审议通过 ...

证券代码：301188 证券简称：力诺药包 公告编号：2025-072 债券代码：123221 债券简称：力诺转债 山东力诺医药包装股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为完善山东力诺医药包装股份有限公司（以下简称"公司"）风险管理体系， 降低公司运营风险，保障公司、董事、监事及高级管理人员的权益，促进公司董 事、监事及高级管理人员充分行使权利、履行职责，促进公司稳健发展，保障股 东特别是中小投资者的权益，根据《上市公司治理准则》等相关规定，公司拟为 公司及全体董事、监事、高级管理人员及其他有关责任人继续购买责任保险（以 下简称"董监高责任险"）。公司于2025年8月19日召开第四届董事会第十二次会 议、第四届监事会第十一次会议，审议了《关于购买董监高责任险的议案》，全 体董事、监事对该议案均回避表决，该议案尚需提交公司2025年第二次临时股东 会审议。现将相关情况公告如下： 一、董监高责任险方案 的保险合同为准。 公司于2025年8月19日召开第四届董事会第十二次会议、第四届监事会第十 一次会议，审议了《关于购买董监高责任险的议案》。 ...

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

Transaction Overview - Shandong Linuo Pharmaceutical Packaging Co., Ltd. has approved an external investment to acquire equity by signing a share transfer agreement with several parties, including Shanghai Miaoxiang Enterprise Management Consulting Co., Ltd. and others [1][2] - The company will acquire a total of 34,046,471 shares of Suzhou Chuangyang New Materials Technology Co., Ltd. for a total consideration of 84,000,000.00 yuan [1][9] - The transaction does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2][3] Financial Assessment - The market value of the total equity of the target company was assessed at 280.98 million yuan as of December 31, 2024 [2] - The transfer price was determined based on the assessment report and the closing price of the stock on the day before the agreement was signed [10] Target Company Information - Suzhou Chuangyang New Materials Technology Co., Ltd. is a high-tech enterprise primarily engaged in the research, production, and sales of medical packaging materials [6] - The company has a registered capital of 113.49 million yuan and operates in the pharmaceutical manufacturing sector [6] Financial Performance of Target Company - The total assets of the target company were approximately 687.06 million yuan in 2023, with total liabilities of about 377.14 million yuan, resulting in a net asset of approximately 304.48 million yuan [8] - The target company reported an operating income of approximately 253.10 million yuan and a net profit of approximately 11.23 million yuan for the year 2023 [8] Shareholding Structure Post-Transaction - After the acquisition, Shandong Linuo will hold 30% of the shares in the target company, while the actual controllers will still maintain control over the majority of shares [7][20] - The shareholding structure will not change the control of the target company [7] Strategic Implications - This transaction is aimed at enhancing the company's long-term development strategy and resource integration, allowing for a more comprehensive product offering to downstream customers [20] - The acquisition is expected to open up growth opportunities for sustainable and high-quality development [20]

山东力诺医药包装股份有限公司 第四届董事会独立董事 2025 年第五次专门会议审核意见 根据《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》 《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律、法规和规范性文件以及《公司章程》的有关规定，山东力诺医药包装股份有 限公司（以下简称"公司"）独立董事召开了第四届董事会独立董事 2025 年第五 次专门会议，审议通过了《关于公司<2025 年半年度募集资金存放与使用情况的 专项报告>的议案》《关于变更部分募集资金用途的议案》《关于拟对外投资购买 股权的议案》 《关于购买董监高责任险的议案》 经核查，我们认为：本次交易是基于公司业务发展需要，为实现公司长远发 展战略规划而做出的整体安排，有利于整合公司与苏州创扬新材料科技股份有限 公司的资源和优势，实现资源共享、共同发展。本次交易风险可控，投资资金来 源于公司募集资金，不会影响公司生产经营活动和现金流的正常运转，不会对公 司未来财务及经营状况产生重大影响，不存在损害上市公司及股东利益的情形。 我们一致同意本次对外投资购买股权事项。 四、关于购买董监高责任险的审核意见 经核 ...

| 民生证券股份有限公司 | | | | --- | --- | --- | | 关于山东力诺医药包装股份有限公司 | | | | 保荐机构名称：民生证券股份有限公司 | | 被保荐公司简称：力诺药包 | | 保荐代表人姓名：杨桂清 | | 联系电话：0531-82596870 | | 保荐代表人姓名：任耀宗 | | 联系电话：0531-82596870 | | 一、保荐工作概述 | | | | 项目 | | 工作内容 | | （1）是否及时审阅上市公司信息披露 | | | | 是 | | | | 文件 | | | | （2）未及时审阅上市公司信息披露文 | | | | 无 | | | | 件的次数 | | | | 规章制度的情况 | | | | （1）是否督导上市公司建立健全规章 | | | | 制度（包括但不限于防止关联方占用公 | | | | 是 | | | | 司资源的制度、募集资金管理制度、内 | | | | 控制度、内部审计制度、关联交易制度） | | | | （2）上市公司是否有效执行相关规章 | | | | 是 | | | | 制度 | | | | （1）查询上市公司募集资金专户次数 | | ...

民生证券股份有限公司 关于山东力诺医药包装股份有限公司 与关联方共同投资设立合资公司暨关联交易的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为山东 力诺医药包装股份有限公司（以下简称"力诺药包"或"公司"）向不特定对象 发行可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等有关规定，对力诺药包与关联方共同投资设立合资公司暨 关联交易事项进行了核查，具体情况如下： 一、关联交易概况 （一）关联交易的基本情况 本次共同投资方力诺集团为公司控股股东力诺投资控股集团有限公司的控 股股东，根据《深圳证券交易所创业板股票上市规则》及《公司章程》等相关规 定，力诺集团为公司关联法人，本次交易构成关联交易。 （三）本次交易的表决情况 公司于 2025 年 8 月 19 日召开第四届董事会第十二次会议，审议通过了《关 于与关联方共同投资设立合资公司暨关联交易的议案》，该议案已经公司第四届 董事会独立董事专门会议 2025 年第五次会议审 ...

Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., is changing the use of part of the raised funds from its convertible bond issuance to better align with its strategic development needs and improve fund utilization efficiency [2][19]. Summary by Sections Fundraising Overview - The company issued 5 million convertible bonds with a net fundraising amount of RMB 491.4447 million, after deducting underwriting fees [2][3]. - As of August 10, 2025, a total of RMB 126.0511 million has been invested from the raised funds, with the remaining amount stored in dedicated bank accounts [3][5]. Change in Fund Usage - The company plans to change the use of RMB 154 million from the "Lightweight Pharmaceutical Glass Bottle (Class I) Industrialization Project" to invest in two new projects: acquiring 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. and the second phase of the high-end pharmaceutical packaging project [3][4]. - The new projects include an investment of RMB 84 million for the equity acquisition and RMB 154 million for the high-end packaging project [3][6]. Reasons for Change - The original project faced delays due to late delivery of construction facilities and longer customer certification cycles, leading to a reduced need for the originally planned funds [5][6]. - The company received a government subsidy of RMB 89.58 million, which decreased the funding requirement for the original project [5][6]. New Investment Projects - The acquisition of 30% equity in Suzhou Chuangyang New Materials is aimed at enhancing the company's product offerings and market share in pharmaceutical packaging [6][10]. - The second phase of the high-end pharmaceutical packaging project focuses on the production of Ready-to-Use (RTU) packaging and pre-filled syringes, with a total investment of RMB 383.3725 million, of which RMB 70 million will come from the raised funds [10][11]. Impact of Changes - The changes in fund usage are expected to enhance the company's operational efficiency and long-term benefits without adversely affecting its existing business or financial status [19][20]. - The company will implement strict internal and external supervision of the fund usage to ensure compliance with relevant regulations [20][21].